FDA Issues Complete Response Letter To VIVUS Regarding New Drug Application For QNEXA®

VIVUS, Inc. (Nasdaq: VVUS) announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form… [...]

Read the rest »

Obesity Drug Lorcaserin Turned Down By FDA Because Of "Cancer Risks"

Citing cancer risks as one of its reasons, lorcaserin, an experimental drug for obesity treatment and maintenance of weight loss, was turned down by the Food and Drug Administration (FDA). The FDA informed lorcaserin makers, Arena Pharmaceuticals Inc… Related Blogs

Read the rest »

FDA Panel Says No To New Obesity Drug Lorcaserin

A US Food and Drug Administration (FDA) advisory committee has voted against recommending federal approval of the new obesity drug lorcaserin, made by Arena Pharmaceuticals Inc under the brand name Lorqess, making it the third time this year that an obesity drug has failed to get the thumbs up from the panel… Related Blogs Obama [...]

Read the rest »


Losethebellyfatnow.com does NOT provide medical advice, diagnosis or treatment. The information in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.

Consumer Notice : This is an Affiliate Website with affiliate links and products.That mean if you buy something from a link,or an ad on this site,or based on our recommendation we may get paid a commission.That's how we pay the bills